NCT03196349View on ClinicalTrials.gov

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

PHASE4TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions
Venous Thromboembolism
Interventions
DRUG

Warfarin

Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3

DRUG

Apixaban 2.5 MG

Will be randomized to receive open label apixaban of 2.5 mg twice daily

DRUG

Rivaroxaban 10 MG

Will be randomized to receive open label rivaroxaban of 10mg daily

Trial Locations (1)

92868

University of California Irvine Medical Center, Orange

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Duke University

OTHER

NCT03196349 - Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism | Biotech Hunter | Biotech Hunter